Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus

Journal of the National Cancer Institute

Volumn 95, Issue 10, 2003, Pages 750-757

  Rudolph, Rebecca E ^a   Vaughan, Thomas L ^b   Kristal, Alan R ^a,b   Blount, Patricia L ^a   Levine, Douglas S ^a   Galipeau, Patricia C ^a   Prevo, Laura J ^a   Sanchez, Carissa A ^a   Rabinovitch, Peter S ^a   Reid, Brian J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P16; PROTEIN P53; SELENIUM; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ANAMNESIS; ANEUPLOIDY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BARRETT ESOPHAGUS; BLOOD LEVEL; CANCER GRADING; CANCER RISK; CANCER STAGING; CHROMOSOME 17P; CHROMOSOME 9P; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA DETERMINATION; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; FEMALE; FLOW CYTOMETRY; GENOTYPE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0038278821     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.10.750     Document Type: Article

References (54)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83: 2049-53.
2. Dolan K, Sutton R, Walker SJ, Morris AI, Campbell F, Williams EM. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer 1999;80:834-42.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
4. Fitzgerald RC, Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis 1998;16:63-80.
5. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
6. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
7. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002. Available at: http://seer.cancer.gov/publicdata/. [Last accessed: 04/04/03.]
8. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105: 383-7.
9. Lerut T, Coosemans W, Van Raemdonck D, Dillemans B, De Leyn P, Marnette JM, et al. Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg 1994;107:1059-65.
10. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93: 1028-32.
11. Cameron AJ. Management of Barrett's esophagus. Mayo Clin Proc 1998; 73:457-61.
12. Riddell RH. Early detection of neoplasia of the esophagus and gastroesophageal junction. Am J Gastroenterol 1996;91:853-63.
13. Beck IT, Champion MC, Lemire S, Thomson AB, Anvari M, Armstrong D, et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol 1997;11(Suppl B):7B-20B.
14. Reid BJ, Barrett MT, Galipeau PC, Sanchez CA, Neshat K, Cowan DS, et al. Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev 1996;5(Suppl 2):57-65.
15. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
16. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
17. Cameron AJ. Epidemiologic studies and the development of Barrett's esophagus. Endoscopy 1993;25:635-6.
18. Vaughan TL. The esophagus. In: Franco EL, Rohan TE, editors. Cancer precursors: epidemiology, detection and prevention. New York (NY): Springer-Verlag; 2002. p. 96-116.
19. Census 2000 Summary File 1 (SF1). U.S. Census Bureau; October 2001. Available at: http://www.census.gov/prod/2001pubs/c2kbr01-12.pdf. [Last accessed: 04/04/03].
20. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999;20:1657-66.
21. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
22. Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst 2000;92:1753-63.
23. Comstock GW, Bush TL, Helzlsouer K. Serum retinol, beta-carotene, vitamin E, and selenium as related to subsequent cancer of specific sites. Am J Epidemiol 1992;135:115-21.
24. World Cancer Research Fund Panel. Food, nutrition, and the prevention of cancer: a global perspective. Washington (DC): American Institute for Cancer Research; 1997. p. 419-20.
25. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
26. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
27. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999;91:2087-95.
28. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
29. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-20.
30. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89: 1277-84.
31. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
32. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
33. Ericson SP, McHalsky ML, Rabinow BE, Kronholm KG, Arceo CS, Weltzer JA, et al. Sampling and analysis techniques for monitoring serum for trace elements. Clin Chem 1986;32:1350-6.
34. Goodman GE, Thornquist M, Kestin M, Metch B, Anderson G, Omenn GS. The association between participant characteristics and serum concentrations of beta-carotene, retinol, retinyl palmitate, and alpha-tocopherol among participants in the Carotene and Retinol Efficacy Trial (CARET) for prevention of lung cancer. Cancer Epidemiol Biomarkers Prev 1996;5: 815-21.
35. Lee W, Roberts SM, Labbe RF. Ascorbic acid determination with an automated enzymatic procedure. Clin Chem 1997;43:154-7.
36. Levine DS, Reid BJ. Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc 1991;37:332-7.
37. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1-11.
38. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-93.
39. Ofman JJ, Shaheen NJ, Desai AA, Moody B, Bozymski EM, Weinstein WM. The quality of care in Barrett's esophagus: endoscopist and pathologist practices. Am J Gastroenterol 2001;96:876-81.
40. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
41. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 1999;9:482-91.
42. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
43. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
44. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-29.
45. Hunter DJ, Morris JS, Chute CG, Kushner E, Colditz GA, Stampfer MJ, et al. Predictors of selenium concentration in human toenails. Am J Epidemiol 1990;132:114-22.
46. Stata. Stata Statistical Software, Release 6.0. College Station (TX): Stata Corp.; 1999.
47. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. A report of the panel on dietary antioxidants and related compounds, subcommittees on upper reference levels of nutrients and interpretation and uses of dietary reference intakes, and the standing committee on the scientific evaluation of dietary reference intakes. Food and Nutrition Board. Washington (DC): National Academies Press; 2000. p. 446-7.
48. Blot WJ, Li JY, Taylor PR, Goo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-92.
49. Moe GL, Kristal AR, Levine DS, Vaughan TL, Reid BJ. Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer 2000;36:7-13.
50. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61: 8284-9.
51. Ip C, Thompson HJ, Ganther BE. Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland. Cancer Epidemiol Biomarkers Prev 2000;9:49-54.
52. Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC, et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis 1997;18:1195-202.
53. Patterson BH, Levander OA. Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary. Cancer Epidemiol Biomarkers Prev 1997;6:63-9.
54. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.